CONTENTS 6 IP news
10 AIPPI, Palais Des Congrès, Paris The 42nd AIPPI Intellectual Property Congress featured contributions from some of the most infl uential fi gures in intellectual property and a lively debate among senior judges on the scope of patentability across jurisdictions
11 CIPA, the Lancaster London Hotel, London
Patent attorneys amassed at a London hotel to talk IP of the past decade and the next. WIPR looks at the highlights.
12 Judging dread: what is the EEUPC?
Intellectual property is a booming business these days, and Europe’s myriad personalities are seen as a hindrance to cheap and effective patent protection. A European patent is obtainable, but enforcement is riddled with practical problems. WIPR examines the proposed centralised litigation system and how it would affect IP professionals on the ground.
18 Consumers fi rst: GlaxoSmithKline on trademarks
People often think that IP in the healthcare sector is all about patents. But while GlaxoSmithKline certainly has a patent portfolio to protect, it also takes a strident approach to enforcing its trademarks and defending its brands. WIPR talks to Emma Stopford, GSK’s vice president for Consumer Healthcare Trademarks, about the company’s strategy.
22 Back to basics: renewing the foundations of innovation
The economic crisis has caused companies and governments alike to reassess their spending. Jim Greenwood explains why imperilling intellectual property protection for the biotechnology industry would be the worst possible outcome.
26 ANDA one, ANDA too?
David Cornwell and Kevin McCabe describe the complex process for obtaining FDA approval for generic and biosimilar drugs, and managing patent disputes with approved companies.
30 Will the future of gene patents be “markedly different” after Myriad?
A US district court decision threatens the future of so-called ‘gene patents’ in the US. Lee Crews and Vicki Norton look at the current position and assess the possible futures for the case.
34 Baker & McKenzie: counterfeit medicines—
the quintessential borderless crime The global spread of counterfeit pharmaceuticals presents a formidable challenge to public health. WIPR asked lawyers from Baker & McKenzie offi ces in Australia, Brazil, Canada, China, Italy, Switzerland, Spain and the UK about this growing menace and what IP rights owners can do.
40 IP Summit—Towards an EU patent
People have been talking about single Europe-wide patent for more than 60 years, but political concerns always seem to get in the way. But with an EU Council proposal on the table and apparent international will to get things done, many commentators feel that it’s now or never. WIPR talks to four key stakeholders about what the future holds.
4 World Intellectual Property Review November/December 2010
www.worldipreview.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108